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ABSTRACT 
 
 
Context: The optimal measure of vitamin D(D) status is unknown. 
 
 
Objective: Directly measure circulating free 25(OH)D concentrations and relationships to total 
 
25(OH)D in a clinically diverse sample of humans. 
 
Design: Cross-sectional analysis 
 
 
Setting: Seven academic sites 
 
 
Patients: 1661 adults: (healthy(n=211), pre-diabetic(n=479), outpatients(n=783), 
 
cirrhotic(n=90), pregnant(n=20), nursing home(n=79)) 
 
Interventions: Merge research data on circulating free 25(OH)D (directly measured 
 
immunoassay), total 25(OH)D (LC/MS/MS), D binding protein (DBP by radial (polyclonal) 
 
immunodiffusion assay)), albumin, creatinine, iPTH and DBP haplotype 
 
Main outcome measures: Distribution of free 25(OH)D (ANOVA with Bonferroni correction 
 
for post hoc comparisons) and relationships between free and total 25(OH)D (mixed effects 
 
modeling incorporating clinical condition, DBP haplotype with sex, race, eGFR, BMI and other 
 
covariates). 
 
Results: Free 25(OH)D was 4.7 1.8 pg/mL (mean+SD) in healthy and 4.3+1.9 pg/mL in 
 
outpatients with 0.5-8.1 pg/mL and 0.9-8.1 pg/mL encompassing 95% of healthy and outpatients, 
 
respectively. Free 25(OH)D was higher in cirrhotics (7.1+3.0 pg/mL, p<.0033) and nursing 
 
home residents (7.9+2.1pg/mL, p<.0033) compared to other groups and differed between whites 
 
and blacks (p<.0033) and between DBP haplotypes (p<.0001). Mixed effects modeling of 
 
relationships between free and total 25(OH)D identified clinical conditions (cirrhotic>nursing 
 
home>prediabetic > outpatient > pregnant), and BMI (lesser effect) as covariates affecting 
 
relationships but not eGFR, sex, race or DBP haplotype. 
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Conclusions: Total 25(OH)D, health condition, race and DBP haplotype affected free 
 
25(OH)D, but only health conditions and BMI affected relationships between total and free 
 
25(OH) D. Clinical importance of free 25(OH)D needs to be established in studies assessing 
 
outcomes. 
 
 
 
Free 25(OH)D levels were affected by clinical conditions as well as race, BMI, or DBP 
 
haplotype. Relationships between free and total 25(OH)D were only affected by clinical 
 
conditions and BMI. 
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1.  Introduction 
 
The adequacy of vitamin D status is usually assessed by measurement of total circulating 25(OH) 
 
vitamin D (25(OH)D) levels. Total circulating 25(OH)D includes 25(OH)D bound to vitamin D 
 
binding protein (DBP) estimated to be about 85% of total with about 10-15% bound to albumin 
 
and a very small fraction as free or unbound 25(OH)D. As DBP is the main carrier for 25(OH)D 
 
and other vitamin D metabolites, its concentration and affinity are the main drivers of the free 
 
concentration of 25(OH)D and other D metabolites. If the free hormone hypothesis applies to 
 
vitamin D biology, only free 25(OH)D is available for conversion to active 1 ,25(OH)2 D that 
 
interacts with the vitamin D receptor regulating hundreds of genes in most cells. It has been 
 
shown that health conditions such as cirrhosis that is associated with protein synthetic 
 
dysfunction resulting in decreased DBP as well as albumin and pregnancy that is associated with 
 
increased protein synthesis and DBP in the second and third trimesters alter levels of free 
 
25(OH)D inversely to the changes in DBP. (1-3). There is uncertainty regarding DBP genetic 
 
variant effects on free 25(OH)D levels but in vitro DBP affinity constants for 25(OH)D that 
 
differ between DBP haplotypes would predict altered 25(OH)D binding and differing free 
 
25(OH)D levels. (4-7) Altered albumin concentrations such as the lower levels reported in the 
 
frail elderly or nursing home residents (8) could also alter free 25(OH)D concentrations, albeit to 
 
a smaller extent than changes in DBP. Thus, total 25(OH)D may not accurately reflect levels 
 
available for cellular uptake with the exception of cells in the kidney or parathyroid capable of 
 
megalin/cubilin-mediated internalization of DBP-bound 25(OH)D. (9) 
 
Primary goals of this work were to combine data from human investigations involving direct 
 
measurement of free 25(OH)D to a) P,(10) in the very elderly such as nursing home patients or 
 
women with osteoporosis likely to receive D supplementation or receive exogenous female sex 
 
hormones in whom free 25(OH)D data are not available; and, b) to determine relationships 
 
between free and total 25(OH)D in these clinical conditions and disease states, and different DBP 
 
haplotypes. Our findings provide a measure of the normal range of free 25(OH)D concentrations 
 
as well as new observations on factors that do and do not alter relationships between free and 
 
total 25(OH)D in clinical populations. 
 
2.  Subjects and Methods 
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A. Subjects. Investigators who directly measured free 25(OH)D in clinical investigations 
 
contributed de-identified data. Adult groups sampled included: healthy subjects, medically 
 
stable community-dwelling outpatients enrolled in longitudinal or D dosing studies, pre- 
 
diabetics, medically stable nursing home residents >65 years of age, stable subjects with 
 
cirrhosis, and pregnant women (second or third trimester).(2, 11-26) Subjects provided 
 
informed consent for research approved by the Institutional Review Board of the respective 
 
organizations. For investigators, sites, and subject description see Appendix. 
 
1. Free 25(OH)D Levels. Direct measurement of free 25(OH)D concentrations was by 
 
immunoassay (Future Diagnostics B.V., Wijchen, The Netherlands, http://www.future- 
 
diagnostics.nl/) as described. (23) In brief, an antibody to 25(OH)D is pre-coated onto a 
 
microtiterplate and serum samples and calibrators added. Free 25(OH)D is captured during 
 
this first incubation step, and after washing, a second incubation with biotin-labeled 
 
25(OH)D analog reacts with non-occupied antibody binding sites (competitive 
 
immunoassay). Finally, after washing and incubating with a streptavidin- peroxidase 
 
conjugate, absorbance [A450nm] is measured using a plate spectrophotometer, where 
 
concentration of free 25(OH)D in the sample is inversely proportional to absorbance in 
each 
 
sample well. Assay calibration was against a symmetric dialysis method. (see 
 
http://www.future-diagnostics.nl/) Limit of detection (LOD) for blank serum is 0.7 pg/mL; 
 
at 5.02 pg/mL, between-run coefficient of variation (CV) was 6.2% and between-day CV 
 
was 4.5% with a total imprecision CV of 15.7%. Biotin at 4mg/dL was tested for assay 
 
interference and mean % interference was 1% at 6.5 pg/mL, 4% at 10.6 pg/mL and 1% at 
 
15.7 pg/mL: free 25(OH)D. Assays were performed at Future Diagnostics B.V. except for 
 
measurements in pre-diabetics performed in Tromso using the Future Diagnostics B.V. kit 
 
with the same technique calibrated over the range of 0.1-35 pg/mL with LOD of 2.8 pg/mL, 
 
with inter- and intra-assay CVs <10%. (25)  
2. Total 25(OH)D was determined by liquid chromatography tandem mass spectrometry (LC 
 
MS/MS) using National Institute of Standards and Technology (NIST) reference standard 
 
(U.S. sites participated in National Institutes of Health Office of Dietary Supplements 
 
funded quality assurance program for analysis of D metabolites in human serum; European 
 
sites participated in the external quality program DEQAS with the exception that two-thirds 
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of samples from cirrhotics were by immunoassay (Diasorin (LIAISON), and the results 
 
converted to (LC MS/MS) equivalent by the manufacturer provided calibration factor.  
3. DBP was measured by radial immunodiffusion (polyclonal) assay (KU Leuven, Belgium) 
 
for all groups except pregnant (monoclonal ELISA R&D Systems (Minneapolis, MN)).  
4. Albumin, creatinine, calcium, were measured with autoanalysers in clinical laboratories. 
 
iPTH was measured by multiple immunoassays: two-site sandwich immunoassay using 
 
direct chemiluminometric technology (ADVIA Centaur, Siemens, Malvern, PA, for UCSF 
 
samples), Diasorin immunoradiometric assay (for Creighton University samples), 
automated clinical chemistry analyzer (Immulite 2000, Siemens Healthcare Diagnostics, 
Los Angeles, CA, USA for Tromso Norway and UK samples), and by Scantibodies 
immunoradiometric assay (Santee, CA) for MrOs samples. Assay method was coded. 
 
5. DBP haplotyping (959 subjects). In 471 prediabetics from University of Tromso haplotyping 
 
was done by KBioscience (http://www.kbioscience.co.uk) using the KBioscience 
 
Competitive Allele-specific PCR genotyping system; in 205 young and older men and 
 
women from Sheffield England at Sheffield Children’s Hospital, United Kingdom a 
 
pyrosequencing assay was developed with PSQ software (version 1.0.6; Qiagen) to detect 
 
rs4588 and rs7041 polymorphisms; in 254 older community outpatient men (multiple U.S. 
 
MrOS sites), two nonsynonymous GC single nucleotide polymorphisms were used to 
define GC haplotypes, rs4588 (Thr436Lys) and rs7041 (Asp432Glu), and in 29 young 
normals (MRC/Gambia) samples were analyzed at Vesalius Research Center (Katholieke 
Universiteit, Leuven, Belgium) by iPLEX technology on a MassARRAY compact analyzer 
(Sequenom Inc). 
  
C. Data analysis. Demographic, clinical characteristics, and assay results are presented as mean 
 
S. D. Analysis of variance for trends followed by post hoc analyses for between group 
 
comparisons using Bonferroni correction for multiple comparisons was used to test for 
 
differences in total, free, or per cent free 25(OH)D between clinical groups, DBP haplotypes 
 
or self-reported racial groups. Relationships between free and total 25(OH)D were examined 
 
using a mixed effects model incorporating clinical condition, DBP haplotypes with sex, race, 
 
eGFR, BMI and other biologically plausible covariates and interactions. Relationships 
 
between free or total 25(OH)D and iPTH were examined in the same manner including iPTH 
 
assay method as a covariate. Analyses were performed in R (R Core Team (2016). R: A 
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language and environment for statistical computing. R Foundation for Statistical Computing, 
 
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/) using the function 
 
lmer from the package lme4).  The fixed effect part of the model takes the form Free = a + (b 
 
+c COV)Total, where a is the intercept, b is the slope of the relationship Free vs Total, and c 
 
is a vector of parameters quantifying the relationship of the slope with covariates. Slopes are 
 
assumed to be normally distributed across individuals. Model selection was conducted using 
 
standard procedures according to the Akaike Criterion (27) and visual inspection of 
 
diagnostic plots. After model selection, comparisons to the reference group were computed 
 
according to 2-sided t-test using the Satterthwaite approximation (R lmerTest). Exploratory 
 
analyses of effects of sex hormones in women were performed using linear regression.  
 
3.  RESULTS  
A. Subject data. Data were from 1661 subjects. Demographic characteristics by clinical 
 
group (normal, pre-diabetic, community-dwelling outpatient, cirrhotic, pregnant, nursing 
 
home (NH)) estimated glomerular filtration rate (eGFR), albumin, calcium, albumin- 
 
corrected calcium, DBP, total and free 25(OH)D, and iPTH are in Table 1. 25(OH)D2 was 
 
identified in no pregnant, 10% of nursing home residents, 25% of cirrhotics, and 61% of 
 
normals and outpatients). Average 25(OH)D2 was < 7% of total in normals and 
 
outpatients and 24% of total in cirrhotics. No relationship was detected between free 
 
25(OH)D and 25(OH)D2. Assays measuring C3-epimer of 25(OH)D were used in 498 
 
samples and C3-epimer was detected in 296 (59%). C3-epimer concentrations over 1 
 
ng/mL were not detected until total 25(OH)D exceeded 20 ng/mL; C3-epimer was < 2 
 
ng/mL at total 25(OH)D up to 30 ng/mL.  
B. Free 25(OH)D Distribution. Distribution of free 25(OH)D concentrations by clinical 
 
group is shown in Figure 1. Data reflected steady-state conditions with and without D 
 
supplementation as part of clinical care (but not during dose titration studies). Free 
 
25(OH)D levels from 0.5 to 8.1 pg/mL include 95% of healthy subjects and is similar to 
 
the 0.9- 8.1 pg/mL range encompassing 95% of the almost three times larger group of 
 
stable outpatients. Significant effects of clinical condition on free 25(OH)D, DBP, total 
 
25(OH)D, and per cent free 25(OH)D were detected (ANOVA p<.0001; Table 1). The 
 
highest mean free 25(OH)D was in NH residents accompanied by higher total 25(OH)D 
 
and lower DBP than normals, outpatients, prediabetics and pregnant women, but higher 
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DBP than in cirrhotics (p<.0033). The next highest mean free 25(OH)D was in cirrhotics 
 
(higher than healthy, pregnant, prediabetic, and outpatients (post hoc p<.0033 for all). 
 
Between group differences were detected for all comparisons (post hoc p<.0033) except 
 
normals vs. pregnant or outpatients, and for pregnant vs. outpatients. Both DBP and 
total 25(OH)D were lowest in cirrhotics. Pregnant women had the second highest total 
25(OH)D levels and the highest DBP (post hoc p<.0033), despite measurement by a 
less sensitive assay. Albumin concentrations were not correlated with DBP (r2= 0.0004, 
 
p=0.83) in the absence of pregnancy or cirrhosis. Per cent free 25(OH)D was higher in 
 
cirrhotics and nursing home residents compared to other clinical groups (post hoc 
 
p<.0033) and between group comparisons were significant for all but normals compared 
 
to pregnant or outpatients, and for pregnant vs. outpatients.  
C. Effects of race and DBP haplotype. Genotype data were available for 959 (outpatients, 
 
prediabetics and normals, Table 2). Ninety-eight were of self-reported black race, 860 
 
white and 1 of self-reported other race. Differences in free 25(OH)D between whites and 
 
blacks were detected (4.9 ± 1.9 vs. 4.0 ±1.5 pg/mL, respectively, p<.0033). As expected, 
 
the 1f allele was more common in blacks and the 1s allele more common in whites. 
 
(Table 2).  Gc 2/2 haplotype was present in 5.5% of whites and no blacks. DBP 
 
haplotype had significant effects on total 25(OH)D, free 25(OH)D, and DBP (ANOVA, 
 
p<.0001). The lowest total and free 25(OH)D were seen with the least frequent Gc 2/2 
 
haplotype (4.2 ±2.2 pg/mL). Total and free 25(OH)D were higher in the presence of 1s 
 
alleles. Post hoc analyses detected lower free 25(OH)D levels in 2/2 haplotype 
compared to 1s/1s or 1s/1f haplotypes and in 1f/1f haplotypes compared to 1f/1s 
haplotypes (p<.0033). DBP haplotype also affected percent free 25(OH)D (p<.0001) 
(Figure 2). The lowest percent free was seen with the 1s/1s haplotype that was lower 
compared to 1s/1f, 1f/2, 1f/1f or 1s/2 haplotypes (p<.0033). Percent free was higher with 
1f/1f haplotype compared to 1s/2, and 1f/2 and was higher with 1f/2 compared to the 
1s/2 haplotype (p<.0033). Magnitude of differences, however, were less than observed 
between some clinical conditions. DBP haplotypes differed in DBP concentrations with 
the 2/2 haplotype having the lowest DBP, total, and free 25(OH)D (post hoc p<.0033) yet 
percent free 25(OH)D that was in the middle of observed means. The highest DBP was 
seen with the 1s/1s haplotype that had the highest total and free 25(OH)D but lowest 
percent free 
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25(OH)D. DBP levels were higher for the 1s/1s haplotype compared to any haplotype 
 
with at least one Gc2 allele (p<.0033) but not when compared to haplotypes 1s/1f 
or1f/1f. 
 
DBP levels were significantly lower for haplotype 2/2 compared to 1f/2,1f/1f; and 1s/1f 
 
(p<.0033). No differences were detected between haplotypes 1s/1s vs 1s/1f or 1f/1f; 
1s/2 
 
vs 1f/2; 1s/2 vs 1f/1f; or 1s/1f vs 1f/1f. Differences between haplotypes 1s/1f vs 1f/2 
 
approached (p=.0045) but failed to reach p<.0033 post hoc criteria for significance). 
 
 
D. Relationships between free and total 25(OH)D. Individual data are plotted by clinical 
 
group and DBP haplotype in Figure 3. Linear mixed effects modelling identified 
 
significant contributors to the relationship as the clinical condition and BMI. (see Table 
 
3). Rejected covariates included eGFR and race. Clinically normal subjects are 
 
associated with the baseline slope (b) of the model. The steepest slope (b+0.1577) was 
in 
 
cirrhotics with the lowest DBP, the second steepest slope was in NH subjects with the 
 
second lowest DBP levels, and the least steep slope was in pregnant women with the 
 
highest DBP. Excluding cirrhosis and pregnancy from the model, sex was selected for 
 
inclusion (male sex with coefficient estimate of 0.03  .004). DBP haplotype effects on 
 
the free vs. total 25(OH)D relationship were not detected in subjects (n=959) with these 
 
data. 
 
 
 
E. Relationships between free and total 25(OH)D and iPTH. Both total and free 25(OH)D 
 
concentrations were negatively related to iPTH levels, but the mixed effects model fits 
 
favored total 25(OH)D (coefficient estimate of -0.96 ±0.51). Covariates selected included 
 
BMI (continuous variable) with a small effect (0.02±.004) and iPTH assay method that 
 
varied within the sites precluding further clinical group analyses. 
 
 
 
F. Exploratory analyses- female sex hormones. Forty young non-pregnant and non-cirrhotic 
 
women reported taking oral contraceptives (OC). Total and free 25(OH)D were 21.0+13.1 
 
ng/mL and 3.4+2.2 pg/mL, respectively, not different from total or free 25(OH)D levels of 
 
20.1+8.3 ng/mL and 3.6+1.5 pg/mL in 21 young non-pregnant non-cirrhotic women not taking 
 
oral contraceptives. Relationships between free and total 25(OH)D in oral contraceptive users 
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had a slope of 0.150 (lower 95% confidence interval (C.I.) of 0.126 and upper 95% C.I. of 
 
0.175) compared to slope of 0.125 (lower 95% C.I. of 0.066 and upper 95% C.I. of 0.185) in 
 
non-users (ns). Thirty-five postmenopausal women reported estrogen use for hormone 
 
replacement, and 82 age-health matched women reported no use. Total 25(OH)D 
concentrationswere 24.8+11ng/mL in estrogen users vs. 26.1+10.2 in non-users. Free 25(OH)D 
was 4.4+2 in estrogen users and 4.6+2.2 pg/mL in non-users (ns), and the slope of relationships 
between free and total 25(OH)D did not differ (users: 0.164 (lower 95% CI of 0.136 and upper 95% 
C.I. of 0.195 compared to slope of 0.158, lower 95% C.I. of 0.124 and upper 95% C.I. of 0.192 in 
non-users). DBP data were not available. 
 
 
 
4.  DISCUSSION 
 
 
 
There is currently debate about the best serum measurement to determine vitamin D status. (4) 
 
Circulating levels of 25-hydroxyvitamin D (25(OH)D) are the most commonly used marker 
 
because its concentration in blood is higher than other D metabolites making it easier to measure, 
 
its conversion from vitamin D is substrate dependent with minimal regulation, and it has a 
 
relatively long circulating half-life. However, the free hormone hypothesis postulates that only 
 
non-bound or “free” fraction of hormones that circulates in blood can enter cells and exert 
 
biologic effects. This would suggest that the free fraction is key to the intracrine functions of 
 
vitamin D except in cells such as those in the kidney or parathyroid gland capable of 
 
megalin/cubilin-mediated internalization of DBP-bound 25(OH)D. (9) 
 
Assays to directly measure free 25(OH)D are not currently applied in clinical care but have been 
utilized in research investigations. It has been demonstrated that directly measured free 
25(OH)D concentrations differ from estimated (calculated) free 25(OH)D concentrations based 
 
on DBP assays using monoclonal or polyclonal antibodies and single or DBP haplotype estimated 
DBP dissociation constants. (2, 3, 6, 19, 21-23, 28) Directly measured free 25(OH)D has also been 
reported to correlate better than total 25(OH)D with some biologic measurements (2, 3, 6, 19, 21-
23, 28), whereas other reports do not report a stronger relationship (summarized in (4-7)). Most 
investigations, however, have small sample sizes or selected populations such that the distribution 
of free 25(OH)D concentrations in many clinical populations is unknown. 
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This paper is the compilation of data from an international Working Group of Vitamin D 
 
investigators in order to describe free 25(OH)D concentrations in a wide range of people with 
 
various clinical conditions. The data were from healthy young and older people, people with 
 
pre-diabetes, community-dwelling outpatients enrolled in longitudinal studies or vitamin D 
 
studies, pre- and post-menopausal women with low vitamin D status, pregnant women, 
 
cirrhotics, and nursing home residents with multiple morbidities enrolled in observational or 
 
vitamin D studies. A major strength is that our international data represent by far the largest and 
 
most diverse sample of adults studied to date and included patients with conditions that alter both 
 
free 25(OH)D levels and the relationship between free and total 25(OH)D, groups for whom 
 
these data have not been previously available. Importantly, 98% of DBP measures were 
 
performed with one polyclonal method at one laboratory, and 95.8% of 25(OH)D measures were 
 
performed by labs participating in quality standardization programs (National Institute of 
 
Standards and Technology (NIST) or Vitamin D External Quality Assessment Scheme 
 
(DEQAS)) and 100% of free 25(OH)D measurements were performed using the same method.  
 
 
A strict definition of “normal” subjects was used to identify people with normal laboratory 
 
chemistry tests, no known chronic medical diseases, and no chronic oral medications excepting 
 
thyroid, hormone replacement therapy, oral contraceptives or dietary supplements. In these 
 
individuals, the mean concentration of free 25(OH)D was 4.3 1.9 pg/mL when mean total 
 
25(OH)D concentration was 21.9 9.9 ng/mL. A range from 0.5 to 8.1 pg/mL included 95% of 
 
healthy normal subjects and was similar to the 0.9- 8.1 pg/mL range encompassing 95% of the 
 
nearly three times larger group of stable outpatients. Mean free and total 25(OH)D 
 
concentrations as well as percent free were slightly higher in prediabetics yet the upper bound of 
 
the 95% confidence interval was similar at 8.9 pg/mL. Free 25(OH)D measurements in pre- 
 
diabetics was performed using the same technique but at a different site than all other assays and 
 
some assay variation may explain the small differences (as some diabetics were included in the 
 
outpatient samples and did not show either higher free or percent free 25(OH)D (data not 
 
shown). In our prior observations in pregnant women and a subset of the cirrhotics, DBP was 
 
measured using a monoclonal antibody DBP assay. (1-3, 23) In the current analyses a polyclonal 
 
antibody was used in the radial immunodiffusion assay performed at the same laboratory for all 
 
groups with the exception of the pregnant women. The data on the current larger group of 
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cirrhotics are consistent with early reports of lower DBP with higher directly measured mean 
 
free 25(OH)D despite lower total 25 (OH)D levels. (26) The data from pregnant women mirror 
 
the almost two-fold higher DBP initially reported in pregnant women in the second and third 
 
trimester compared to non-pregnant women (29, 30) and with less variability in free 25(OH)D. 
 
Although the group of pregnant women was small, similar mean free 25(OH)D with lesser 
 
variability than in other groups has been reproduced using the same methods in a larger group of 
 
about 300 Caucasian women, despite somewhat higher DBP in the second and third trimesters 
 
when measured by ELISA with a polyclonal antibody.(31) We had limited data on women 
 
reporting oral contraceptive use or hormone replacement therapy with estrogen, but free 
 
25(OH)D levels and relationships between total and free 25(OH)D did not appear to be 
 
significantly influenced by use of these agents at currently prescribed dosages and routes of 
 
administration. 
 
 
 
An unexpected observation was that mean free 25(OH)D was higher in the nursing home 
 
residents with distribution of values shifted toward higher concentrations. Likely contributors 
 
were both the lower DBP levels and the higher total 25(OH)D in the nursing home residents 
 
compared to the normal subjects, prediabetics, community-dwelling and pregnant subjects. 
 
Mean albumin concentrations were slightly lower in the nursing home residents compared to 
 
normals, outpatients, or prediabetics but as only 12-15% of 25(OH)D is bound to albumin it is 
 
unlikely to have been a major factor. Inflammation and/or elevated cytokines that accompany 
 
very old age (32) or multiple morbidities could also alter affinity of 25(OH)D to DBP. Whatever 
 
the underlying mechanisms, both percent free 25(OH)D concentrations and the relationship 
 
between free and total 25(OH)D differ in pregnant women, people with cirrhosis, and elderly 
 
people with multiple morbidities compared to normals or community-dwelling outpatients, and 
 
relationships are affected to a much smaller extent by BMI in all groups. It also appears that 
 
stable medical conditions such as hypertension, prediabetes, diabetes, osteoporosis, or mild renal 
 
disease do not appear to significantly alter relationships between free and total 25(OH)D. 
 
 
 
Free 25(OH)D concentrations are related to total 25(OH)D concentrations as well as albumin and 
 
DBP and their binding affinities for 25(OH)D. (29) DBP is a highly polymorphic protein. (33) 
 
Our sample included whites and blacks and several Asians, and distribution of DBP haplotypes 
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mirrored reported racial differences in that black (and Chinese) populations are more likely to 
 
carry the Gc1f allele and whites more likely to possess the Gc1s and the less frequent Gc2 allele. 
 
(34) DBP haplotype affected DBP and both total and free 25(OH)D concentrations. The Gc2/2 
 
haplotypes and presence of 1f alleles were associated with lower total 25(OH)D concentrations 
 
as previously reported. (35)  Gc1f has been reported to have the highest affinity and Gc2 the 
 
lowest affinity for vitamin D and its metabolites, but this has not been uniformly detected. (7, 33, 
 
36, 37) In our sample, the highest percent free was seen with the 1f/1f haplotype and 1f/2 
 
haplotypes and the lowest percent free was seen with 1s/1s despite similar DBP concentrations. 
 
Mean percent free 25(OH)D in people with the 2/2 haplotype was in the midpoint of the range 
 
and did not differ significantly from the 1s/1f or 1s/ 2 haplotypes. These data do not support the 
 
earlier report of Gc1f having the highest and Gc2 having the lowest affinity for 25(OH)D. The 
 
maximum mean percent differences between haplotypes was on the order of about 19-24 percent. 
 
DBP concentrations differed between some haplotypes, and free 25(OH)D concentrations were 
 
in the expected relationship—i.e. higher free 25(OH)D concentrations with lower DBP, but the 
 
percent free 25(OH)D did not show the same relationship. In contrast to differences in percent 
 
free 25(OH)D by DBP haplotype, haplotype was not selected as a significant covariate in the 
 
linear mixed effects model of relationships between free and total 25(OH)D in these individuals. 
 
This suggests that haplotype does not have a marked effect on the relationship. We did not have 
 
DBP haplotype data on cirrhotics, nursing home residents or pregnant women to allow 
 
comparisons of clinical condition effects to haplotype effects in the same model. Nevertheless, 
 
the magnitude of differences seen between the clinical groups was greater than that seen between 
 
DBP haplotypes. 
 
 
This study has limitations. Data were not from random population-wide samples and analyses of 
 
BMI, sex, race or other subgroup effects might not be representative of all populations. Samples 
 
were from medically stable individuals and may not apply to acute medical conditions. The only 
 
potential biomarker for vitamin D status analyzed was iPTH with differing methods in clinical 
 
laboratories limiting our analyses. However, the parathyroid gland has the megalin/cubilin 
 
mechanism for cellular uptake of DBP, so PTH levels are unlikely to discriminate between free 
 
and total 25(OH)D effects on biological function. Bone biomarkers were not assessed. Bone 
 
density has been reported to correlate better with measures of free than total 25(OH)D in the 
14 15 
 
 
prediabetics included in the current analyses (19), but others have found similar relations 
 
between markers of bone metabolism and free or total 25(OH)D. (38) However, D and bone 
 
relationships are somewhat difficult to interpret as measures of vitamin D and its metabolites are 
 
often done only at a single timepoint while bone density is the result of cumulative time effects. 
 
As many of the subjects sampled received D supplementation, we could not address seasonal 
 
effects. 
 
 
 
5. CONCLUSIONS. Free 25(OH)D concentrations are affected by health conditions in 
 
addition to total 25(OH)D concentrations and DBP haplotype. Free 25(OH)D distributions were 
 
similar in normal individuals and stable community-dwelling outpatients with 95% within the 
 
range of 0.5 to 8.1 pg/mL and 0.9- 8.1 pg/mL, respectively. Per cent free 25(OH)D was affected 
 
by clinical condition (cirrhotics>nursing home residents, >outpatient, >normal>pregnant), self- 
 
reported race (black>white>Asian), and DBP haplotype (1f/1f +1f/2>1f/1s,2/2, 1s/2>1s/1s). 
 
Relationships between free and total 25(OH)D were influenced by BMI to a small extent and to a 
 
larger extent by health conditions with cirrhotics and nursing home residents having the steepest 
 
slopes and pregnant women the least steep without significant effects of DBP haplotype detected 
 
in mixed effects models. Clinical outcomes data other than PTH levels are needed to determine 
 
the role of free 25(OH)D measurements in clinical decision-making with the growing recognition 
 
of the role that vitamin D and its metabolites play in promoting optimal health beyond bone and 
 
calcium absorption metabolism. (39) Currently, most vitamin D intake recommendations are 
 
based on immunoassay-measured total 25(OH)D levels associated with lower risk of 
 
osteoporotic fractures in postmenopausal women. (40) Clinicaltrials.gov lists over 600 
 
completed phase 2, 3, and 4 trials of vitamin D relationships to various health conditions, 59 
 
active and not recruiting, 149 clinical trials currently recruiting and 36 in the planning stages. 
 
(https:\\clinical trials.gov accessed May 30, 2018). Results from two very large randomized 
 
double-blind trials investigating vitamin D supplementation effects on cancer, cardiovascular 
 
disease and mortality (VITAL:NCT01169259, and VIDAL:ISRCTN46328341) will soon be 
 
available and will provide data on relationships with total 25(OH)D. However, to the extent 
 
that the free hormone hypothesis applies to cellular availability of vitamin D metabolites, total 
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25(OH)D measurements may be misleading in subjects with altered total to free relationships 
 
and analysis of free 25(OH)D could provide further insights. 
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Table 1. Description of Populations Sampled and Serum Measurements by Clinical Subgroups  
 
 Normal Community- Prediabetics Cirrhotics Nursing Home Pregnant 
  dwelling     
  Outpatients     
N (%) 279 (16.8) 714 (43) 479 (28.8) 90 (5.4) 79 (4.8) 20 (1.2) 
Age 36.6+8.5 68.7+8.5 62+8.6 58.0+8.8 87.4 +8.0 30.7 +6.9 
Sex –Women n (%) 178 (63.8) 324 (45.4) 184 (38.4) 36 (40) 51 (64.6) 20 (100) 
Men 90 (32.3) 390 54.6) 295 (61.6) 54 (60) 28 (35.4) 0 (0) 
unknown 11 (3.9) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
Race- White, black 187, 65 518,191 479, 0 69, 11 78, 0 15, 4 
 (67, 23.3) (72.5, 26.8) (100,0) (76.7,12.2) (98.7) (75, 20) 
Asian, other, Nat 12, 1, 2, 12 3, 0,2, 0 0,0,0,0 6, 0, 4 1 1 
Amer, unknown (4.3,0.4,7.2,4.3) 0.4,0,0.3,0)  (6.7, 0,4.4) (1.3) (5) 
Weight (kg) 78.5+18.6 83.7+16.7 88.4+16.6 85.5 +18.8 69.9 +16.4 81.1 +20.9 
BMI 28.0+6.2 29.4+6.0 29.9+4.3 29.1+5.8 27.3+5.8 32.1+7.4 
eGFR 107.1+15.3 79.6+18.1 93.4+2.2 N.A. 63.8+19.4 81.6+5.6 
(ml/min/1.73M
2
)       
Creatinine (mg/dL) 0.8+0.1 1.0+0.3 0.8+0.2 1.0 +0.8 0.9+0.3 -- 
Albumin (mg/dL) 4.3+0.4 4.3+0.3 4.5+0.2 3.2+0.8 3.6+0.4 3.6+0.3 
Calcium (mg/dL) 9.3+0.4 9.4+0.4 9.2+0.3 8.8+0.7 9.0+0.4 9.1+0.6 
Corrected Calcium 9.1+0.3 9.1+0.4 8.8+0.3 9.4+0.6 9.4+0.2 n.a. 
(mg/dL)       
iPTH (pg/mL)^ 42.2+20.0 44.1+24.7 52.8+20.8 38.8+35.3 48.1+25.5 21.8+18.0 
       
Free 25(OH)D 4.3+1.9 4.5+1.8 5.5+1.7 7.1+3.0 9.5±3.8 4.0+1.1 
(pg/mL) •~*       
Total 25 (OH)D 21.9+ 9.9~ 22.5+9.1~ 24.4 +8.7 18.7+ 10.6 34.9±12.8 26.7 + 10.0 
(ng/mL) #~*       
Per Cent Free 0.020+.006 0.021+.008 .023+.006 .040+.020 .028+.006 .016+.006 
25(OH) D*       
D Binding Protein 293±51.1 294.1±36.5 299.2±41.4 175.5±64.7 264.2±38 529±49.5 
(mcg/mL) `* (n=159) (n=495) (n=476) (n=58) (n=78) (n=20)  
  
Data are mean S.D. unless otherwise noted. ^ measured in clinical laboratories by multiple methods. • Assays performed at 
 
Future Diagnostics, BV except prediabetics had assays using same method at the Investigator site. # Assays were by LC 
 
MS/MS except for 69 (of 90) cirrhotics by Diasorin (LIAISON) that were corrected by a calibration factor provided by the 
 
Manufacturer. ~ multiple samples of total and free 25(OH D from some individuals from dose titrations studies. ` D Binding 
 
Protein Measurements by radial immunodiffusion assay (Leuven)—with the exception of pregnant women determined by 
 
R&D assay (in italics).* Significant effect of clinical group (ANOVA, p<.0001),  post hoc between group comparisons were 
 
significant at p<.0033 for all but normals vs. pregnant or outpatients, or for pregnant vs. outpatients.   post hoc between group 
 
comparisons were significant at p<.0033 for all but normals compared to outpatients, or pregnant or cirrhotic, or for pregnant 
 
compared to outpatients or prediabetics.  Post hoc between group comparisons were significant at p<.0033 for all but normals 
 
compared to pregnant or outpatients, or for pregnant vs. outpatients.  Post Hoc between group comparisons were significant 
 
at p<.0033 for all but normals compared to outpatients or prediabetics, or for prediabetics compared to outpatients. 
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Table 2. Free, Total, and Per cent Free 25(OH)D and D Binding Protein by DBP Haplotype  
  
DBP 
 
Haplotype Frequency (%)* 
 
 
 
 
 
 Whites Blacks Other 
 (n=860) (n=98) (n=1) 
1s/1s 31.9 1 0 
1s/2 29 1 100 
1s/1f 22.4 27 0 
2/2 5.5 0 0 
1f/2 8.3 18 0 
1f/1f 3 51 0 
 
Free 25(OH)D Total 25(OH)D Per Cent DBP (RID) 
 
(pg/mL)** (ng/mL)** Free (mcg/mL)** 
 
25(OH)D** 
 
 
 
 
5.1+1.8 25.6 +10.0 .021+.006 308.6 +40 
    n=209 
5.1+ 2.1 23.1 +8.4 .023+.007 287.9 +36.2 
    n=182 
5.4+2.0 24.2 +9.0 .023+.007 304.5 +39.7 
    n=189 
4.1+2.0 17.8 +7.3 .023+.007 260.4 +25.1 
4.7+1.8 
 
+7.7 .026+.010 
n=24 
+34.1 19.6 289.3 
4.4+1.6 18.2+8.2 .026+.008 
n=73 
+43.5 300.1 
    n=73  
 
 
*Significant differences in frequencies of haplotypes between the races for all haplotypes except for Gc1s/1f were detected. 
 
**Statistically significant effects of DBP haplotype were detected for Total, free and per cent free 25 (OH)D concentrations and DBP 
 
(ANOVA, p<.0001; see Fig 2 and text for individual between haplotype post hoc comparisons.)

 
 
 
Table 3. Linear mixed model analysis of Relationship between Free and Total 25(OH)D 
 
  
 
 
Model: Linear mixed effects regression Coefficient S.E. t value p value 
 
 
 
 
Model Selected Covariates     
a (Intercept) 1.291 .0781 16.521 <.000001 
b (slope) 0.186 .0085 22.024 <.000001 
Selected Covariates     
Clinical Class     
Community –dwelling/Outpatients -.0094 .0046 -2.026 <.05 
Prediabetics 0.0245 .0049 5.010 <.000001 
Cirrhotics 0.1577 .0080 19.763 <.000001 
Nursing Home Residents 0.0873 .0064 13.585 <.000001 
Pregnant -.0450 .0126 -0.357 <.0001 
BMI -.0013 .0003 -4.926 <.000001 
 
 
 
The mixed effect model takes the form Free = a + (b +c COV)Total, where a is the intercept, b is the slope of the 
 
relationship Free vs Total 25(OH)D, and c is a vector of parameters quantifying the relationship of the slope with covariates. Variables 
 
tested but not selected included eGFR and race. Sex was not tested in this model. T and p values represent comparisons to the 
baseline slope of the model (normals). 
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Figures 
 
 
Figure 1. 
 
 
 
 Distribution of free 25(OH)D 
 
concentrations are shown for Normal subjects, stable community-dwelling Outpatients, 
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Pregnant women, elderly Nursing Home residents, and Cirrhotics. Free 25(OH)D 
 
concentrations are on the horizontal axis, and the number of subjects is plotted on the 
 
vertical axis. The curved line represents the normal distribution. Data are only study 
 
entry (baseline) concentrations for any subjects enrolled in vitamin D supplementation or 
 
dose titration studies. 
 
 
 
Figure 2. 
 
 
 
Per cent free 25(OH)D concentrations are presented by Clinical Subgroup in the left panel and 
 
by DBP haplotypes in the right panel (subset of n=974).  The box plot shows the 10th, 25th, 
 
median, 75th and 90th percentile values. Individual points represent values above the 90th and 
 
below the 10th percentile. Both clinical subgroup and DBP genotype had significant effects on 
 
per cent free 25(OH)D (ANOVA, p<.0001). *Horizontal parentheses indicate statistically 
 
significant post hoc between group comparisons (meeting Bonferroni criteria of p<.0033). Post 
 
hoc between clinical group comparisons were significant for all but normals compared to 
 
pregnant or outpatients, or for pregnant compared to outpatients. For DBP haplotypes, smaller 
 
but significant differences were detected between the 1s/1s haplotype and 1s/1f, 1f/2, 1f/1f, and 
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1s/2 haplotypes; and between the 1s/2 and 1f/2 and 1f/1f haplotypes and between the 1s/1f and 
 
1f/1f haplotypes. 
 
 
 
Figure 3. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relationships between free and total 25(OH)D by clinical subgroup and DBP haplotype. Total 
 
25(OH)D concentration is plotted on the x axis and free 25(OH)D concentration is plotted on the 
 
y axis. In the left panel, open circles represent data from community-dwelling outpatients, 
 
closed blue circles represent data from older nursing home (NH) residents, closed brown circles 
 
represent data from cirrhotics, pink x represent data from pregnant women, half- filled circles 
 
represent data from prediabetics, and closed green circles indicate data from normal/healthy 
 
subjects. Data include multiple measures in a subset of healthy normal and NH residents enrolled 
 
in vitamin D supplementation studies (n=243 samples). In the right panel, closed blue circles 
 
represent the 1s/1s DBP haplotype, half blue and half white circles represent 1s/2 haplotypes, 
 
solid green circles represent 1s/1f, solid diamonds represent 2/2, open cross hatched diamonds 
 
represent 1f/2, and solid red circles represent 1f/1f. DBP haplotype data were from normals, 
 
community-dwelling outpatients, and prediabetics. Linear mixed modelling detected significant 
 
effects of clinical groupings on the relationship between free and total 25(OH) D (*p<.05, ** 
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p<.0001, *** p<.000001 for comparisons to normal/healthy subjects). Significant effects of 
 
DBP haplotype on the relationship were not detected. 
 
 
 
 
 
6.  APPENDIX Data Sources (and original project support) 
 
 
 
Normal Volunteers and Outpatients 
 
P.I. Janice B. Schwartz, MD, University of California, San Francisco, CA, USA. Participants 
 
were healthy individuals enrolled in comparison studies of vitamin D3 and D2 (unpublished; 
 
n=36). Support: RO1 AG 15982, R56 AG15982 . Community-dwelling outpatients enrolled in 
 
vitamin D dose titration study to normalize 25(OH)D levels to determine the effects on lipid 
 
and/or atorvastatin concentrations (n=131) . (21) Support: RO1 AG 15982, R56 AG15982 
 
P.I. Michael Holick MD, PhD, Boston University School of Medicine, Boston, MA, USA 
 
Participantswere healthy individuals enrolled in vitamin D metabolism studies and comparison 
 
studies of vitamin D3 and D2; n=23 (11) (12, 17) 
 
 
 
P.I. J. Christopher Gallagher MD, Creighton University Medical Center, Omaha, NE, USA (and 
 
Martin Kaufman PhD, Glenville Jones BSc, PhD). Young to middle-aged women (25-45 y) and 
 
post-menopausal with vitamin D insufficiency participating in randomized-blinded studies of the 
 
effects of vitamin D3 400, 800, 1600, 2400, or placebo for 12 months—baseline measurements 
 
were provided for this study (n=336). (14, 15) Support: R01-AG28168, (DOD) W81XWH-07-1- 
 
201. 
 
P.I. Richard Eastell, MD, and Amy L. Evans, Simon Bowles, Mellanby Centre for Bone 
 
Research, University of Sheffield, UK, Jennifier Walsh PhD, K.E. Naylor, Ph.D, K.S. Jones, I. 
 
Schoenmakers, Ph.D. (26) KSJ and IS: Medical Research Council Human Nutrition Research; 
 
IS:Department of Medicine, Norwich Medical School, Faculty of Medicine and Health Sciences 
 
7University of East Anglia, Norwich, NR4 7TJ, UK (healthy and outpatients; n=206 Caucasian 
 
men and women including overweight and obese from South Yorkshire, United Kingdom (12, 
 
17) Support: Department of Health (policy research program 024/0052) and by the Sheffield 
32 
 
 
National Institute for Health Research Clinical Research Facility, the Medical Research Council 
 
(MRC) and the Department for International Development (DFID) (under the MRC/DFID 
 
Concordat; MRC unit programs U105960371 and U123261351). 
 
 
 
P.I. Dr. Rolf Jorde, Tromso Endocrine Resarch Group, UiT the Arctic University of Norway, 
 
9037 Tromsø, Norway and Division of Internal Medicine, University Hospital of North Norway, 
 
9038 Tromsø Norway and Vivan Berg, Laboratory Medicine, University Hospital of North 
 
Norway, 9038 Tromso, Norway. Men and Women with pre-diabetes enrolled in the longitudinal 
 
Tromso study (n=479). (18, 19, 25) Support: Grants from the Novo Nordisk foundation (grant 
 
number R195-A16126), the North Norway Regional Health Authorities (grant 
 
number 6856/SFP1029-12), UiT The Arctic University of Norway, the Norwegian Diabetes 
 
Association, and the Research Council of Norway (grant number 184766). (12, 17) 
 
 
 
P.I.(s) Eric Orwoll, MD, Carrie Nielson, MPH, Ph.D. Osteoporotic Fractures in Men (MrOS) 
 
cohort; n=275 . (22, 41) Recruitment occurred in six US communities, primarily through mass 
 
mailings. Participants were community-dwelling men older than 65 years of age (n=275). 
 
Support: National Institute on Aging, the National Institute of Arthritis and Musculoskeletal and 
 
Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences, and NIH 
 
Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 
 
AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, 
 
U01 AR066160, and UL1 TR000128. Additionally, portions were performed in the 
 
Environmental Molecular Sciences Laboratory operated by Battelle Memorial Institute for the 
 
Department of Energy under Contract DE-AC05-76RL0 1830 and portions were supported by 
 
NIH P41GM103493 . Free 25OHD assay provided by DIAsource ImmunoAssays SA (Belgium) 
 
and Future Diagnostics Solutions BV (Netherlands). 
 
P.I.(s) Inez Schoenmakers, Ph.D. Kerry Jones, Ph.D. Nutrition and Bone Health Group, 
 
Cambridge, UK. Medical Research Council (MRC) Gambian/UK cohorts; n=37. (20, 22) 
 
healthy males, aged 25–39 years, and Gambians were of the Mandinka ethnic group; UK men 
 
were self-classified as white European. Samples were from studies conducted at MRC Keneba, 
 
The Gambia, and MRC Human Nutrition Research, Cambridge, UK. Support: Medical Research 
 
Council (program codes U105960371, U123261351, MC-A760-5QX00) and the Department for 
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International Development (DFID) under the MRC/DFID Concordat agreement.: NIAMS K01 
 
AR062655. NIAMS R01 AR063910. T32 DK007674-20. Research Foundation Flanders (G. 
 
0858.11) and KU Leuven (GOA 15/0/01). 
 
Nursing Home data 
 
P.I. Janice B Schwartz, MD and Daniel Bikle, MD, PhD. University of California, San Francisco, 
 
San Francisco, CA, USA.Support: R21 AG 041660 
 
Participants were clinically stable long-term stay nursing home residents aged 65 and older  
(Jewish Home, San Francisco; n=79) randomized to vitamin D3 doses of 800, 2,000, or 4,000 
 
IU/d, or 50,000 IU/wk for 16 weeks with baseline, eight week and 16 week blood samples for 
 
total 25(OH) vitamin D and free 25(OH)D vitamin D. (24) 
 
Patients with Cirrhosis 
 
P.I. Jennifer Lai, MD (Janice B Schwartz, MD and Daniel Bikle, MD PhD) University of 
 
California, San Francisco, CA. USA. prospective single-center cohort study of adult patients 
 
with cirrhosis who were seen as out patients from October 2012 to March 2014; n=89. Support: 
 
NIH P30 DK026743 (UCSF Liver Center) and an American College of Gastroenterology 
 
Clinical Research Award, NIH R21 AG041660 and NIH RO1 AR050023. (2) 
 
Pregnant Women 
 
P.I.(s) Janice B Schwartz, MD, Naomi Stotland, MD, and Daniel Bikle, MD PhD, University of 
 
California San Francisco, CA, USA. Pregnant women in their second or third trimester of 
 
pregnancy who were seen as outpatients at San Francisco General Hospital, San Francisco, CA, 
 
during 2014. (2) 
 
 
